Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent inhibitor of 12/15-Lipoxygenases (LO) and has potential for research related to type 1 diabetes mellitus. The compound's efficacy in suppressing transendothelial dextran transport, particularly when increased by high glucose or 12(S)-HETE, has been observed in vitro. It has also been shown to mitigate the destruction of the endothelial cell barrier by antagonizing the effect of high glucose on protein phosphorylation, a finding further supported by mouse diabetes mellitus models.
- Potent 12/15-Lipoxygenases (LO) inhibitor
- Potential for research of type 1 diabetes mellitus
- Partially suppresses transendothelial dextran transport
- Mitigates destruction of the endothelial cell barrier
- Antagonizes effect of high glucose on protein phosphorylation